Container Closure Integrity Testing-Practical Aspects and Approaches in the Pharmaceutical Industry

Area of Science:

• Pharmaceutical Manufacturing
• Sterile Drug Products
• Container Closure Integrity

Background:

• Regulatory requirement for parenteral drug product sterility necessitates robust container closure integrity (CCI).
• Current regulatory guidances offer limited detail on CCI assessment, with differing international standards.
• The upcoming revision of USP <1207> aims to provide more detailed guidance, but practical industry questions remain.

Purpose of the Study:

• To address practical considerations and provide industry best practices for container closure system (CCS) qualification and integrity testing.
• To discuss key questions including method selection, primary packaging types, dosage forms, acceptance criteria, sample sizes, artificial leak generation, and in-use testing.
• To offer a European industry perspective on flexible yet appropriate CCI approaches.

Main Methods:

• Discussion among European industry peers to identify and address practical challenges in CCI assessment.
• Review of current regulatory landscapes and the implications of revised guidelines like USP <1207>.
• Consideration of various factors influencing CCI testing, such as deterministic vs. probabilistic methods, packaging, and product type.

Main Results:

• No single gold standard exists for CCI test methods or artificial leak generation.
• Flexibility in CCI approaches is required, tailored to the intended use and product design.
• Key practical questions regarding method choice, acceptance criteria, and testing under storage conditions need careful consideration.

Conclusions:

• A flexible approach to container closure integrity testing is necessary, balancing regulatory compliance with practical application.
• Any CCI strategy must be carefully chosen based on the specific intended use (e.g., qualification, QC) and product characteristics.
• Continued dialogue and sharing of best practices are essential for advancing robust CCI strategies in the pharmaceutical industry.